Insider Transactions in Q3 2023 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2023
|
Shafique Virani Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+14.71%
|
$60,000
$2.22 P/Share
|
|
Jul 13
2023
|
Terry Ann Burrell Director |
SELL
Open market or private sale
|
Direct |
8,275
-13.11%
|
$99,300
$12.59 P/Share
|
|
Jul 12
2023
|
Terry Ann Burrell Director |
SELL
Open market or private sale
|
Direct |
108,725
-19.1%
|
$1,304,700
$12.67 P/Share
|
|
Jul 12
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-69.05%
|
$300,000
$12.44 P/Share
|
|
Jul 12
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,000
+50.0%
|
-
|
|
Jul 12
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,818
-0.85%
|
$381,816
$12.35 P/Share
|
|
Jul 12
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+3.19%
|
$62,500
$2.48 P/Share
|
|
Jul 11
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$53,310
$6.89 P/Share
|
|
Jul 03
2023
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,609
+0.25%
|
-
|
|
Jul 03
2023
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,541
+4.53%
|
-
|
|
Jul 03
2023
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,863
+2.52%
|
-
|
|
Jul 03
2023
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+13.31%
|
-
|